Perspectivas del mercado y visión del analista:
La enfermedad de Crohn es una afección inflamatoria crónica que afecta principalmente al tracto gastrointestinal. Comúnmente afecta la parte final del intestino delgado y el comienzo del intestino grueso. La enfermedad se caracteriza por la inflamación del revestimiento del tracto digestivo, lo que provoca síntomas como dolor abdominal, diarrea y desnutrición. El creciente tamaño del mercado terapéutico para la enfermedad de Crohn se atribuye a la creciente prevalencia de enfermedades en los países occidentales, particularmente en Estados Unidos. Además, las iniciativas estratégicas de las empresas para seguir siendo competitivas en el mercado están impulsando el crecimiento del mercado. Es probable que un aumento significativo en el uso de dispositivos médicos avanzados genere nuevas tendencias en el mercado terapéutico de la enfermedad de Crohn durante el período de pronóstico.
Impulsores y desafíos del crecimiento:
La enfermedad de Crohn es un síndrome del intestino irritable, un trastorno inflamatorio intestinal crónico sin cura específica. Se desconoce la etiología exacta de esta enfermedad, pero la afección es principalmente el resultado de una respuesta inmune inadecuada en el intestino a medicamentos, toxinas, infecciones y microbios intestinales, entre otros factores ambientales, especialmente en un huésped genéticamente susceptible. Según la Biblioteca Nacional de Medicina, la enfermedad de Crohn (EC) es más común en los países desarrollados de Occidente, especialmente en los países de América del Norte y el norte de Europa, y en Nueva Zelanda. La aparición de la enfermedad es más común en personas de 15 a 30 años y de 40 a 60 años, y es más prominente en las zonas urbanas. La incidencia de esta enfermedad es elevada en personas procedentes de países del norte de Europa y de ascendencia judía, es decir, 3,2/1.000. Sin embargo, estudios recientes han demostrado un aumento significativo de la incidencia en Asia, África y Australasia, también debido a la rápida industrialización de la región. Por lo tanto, la asombrosa prevalencia de la enfermedad de Crohn en la región respectiva impulsa el mercado terapéutico de la enfermedad de Crohn.
Según el Instituto Nacional de Salud, la enfermedad de Crohn plantea una carga económica significativa con costos sanitarios directos de aproximadamente 3500 dólares estadounidenses por paciente. por año en Europa. La enfermedad afecta aproximadamente a 322 personas por cada 100.000. Sin embargo, las tasas de prevalencia pueden variar según los países. Es posible que más del 50% de los pacientes con enfermedad de Crohn no sean diagnosticados formalmente o que muestren síntomas similares a los de otras enfermedades del tracto digestivo. La enfermedad de Crohn es más común en mujeres que en hombres, es decir, puede afectar tres veces más mujeres que hombres.
Las empresas involucradas en el desarrollo de fármacos para el síndrome del intestino irritable están tomando medidas constructivas para implementar programas de concientización con el objetivo de para afrontar eficazmente este síndrome creando conciencia sobre los síntomas, diagnósticos y tratamientos. En 2018, Allergan PLC e Ironwood, en colaboración, lanzaron una plataforma de destino digital interactivo para alentar a los pacientes a educarse y tomar medidas contra los trastornos del tracto digestivo. Por lo tanto, la creciente prevalencia del síndrome del intestino irritable impulsa el crecimiento del mercado de terapias para la enfermedad de Crohn.
Perspectivas estratégicas
Segmentación y alcance del informe:
El análisis del mercado de terapias para la enfermedad de Crohn ha sido llevado a cabo considerando los siguientes segmentos: tipo de medicamento, canal de distribución y geografía. Por clase de medicamento, el mercado se segmenta en antiinflamatorios, supresores del sistema inmunológico, antibióticos, biológicos, antidiarreicos y analgésicos. El segmento de productos biológicos tuvo la mayor participación de mercado en 2023. Se espera que el segmento de medicamentos antiinflamatorios registre la CAGR más alta durante 2023-2031.
Según el usuario final, el mercado se divide en farmacias hospitalarias y farmacias clínicas. y otros en línea. El segmento de farmacia hospitalaria representó la mayor cuota de mercado de terapias para la enfermedad de Crohn en 2023. En términos de geografía, el alcance del informe de mercado de terapias para la enfermedad de Crohn implica América del Norte (EE.UU., Canadá y México), Europa (España, Reino Unido, Alemania, Francia, Italia y resto de Europa), Asia Pacífico (Corea del Sur, China, Japón, India, Australia y resto de Asia Pacífico), Medio Oriente y África (Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos y resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y el resto de América del Sur y Central).
Análisis regional:
América del Norte es el mayor contribuyente al mercado mundial de terapias para la enfermedad de Crohn. crecimiento. Se estima que Asia Pacífico registrará la CAGR más alta del mercado durante 2023-2031. El progreso del mercado en América del Norte se atribuye a la creciente incidencia de enfermedades crónicas, los avances tecnológicos y el acceso a productos médicos tecnológicamente avanzados, el aumento de la población geriátrica y la presencia de actores clave del mercado involucrados en el desarrollo de productos nuevos y existentes. Estados Unidos tuvo la mayor participación de mercado de terapias para la enfermedad de Crohn en América del Norte en 2023.
Mercado de terapias para la enfermedad de Crohn, por canal de distribución: 2023 y 2031
Desarrollos de la industria y oportunidades futuras:
< El pronóstico del mercado de Terapéutica de la enfermedad de Crohn se estima sobre la base de varios hallazgos de investigación primaria y secundaria, como publicaciones clave de la empresa, datos de asociaciones y bases de datos. Según los comunicados de prensa de la compañía, los desarrollos clave de los principales actores que operan en el mercado terapéutico de la enfermedad de Crohn se enumeran a continuación:
•En 2023, la Administración de Medicamentos y Alimentos de EE. UU. (FDA) aprobó la primera píldora oral: Rinvoq (upadacitinib): para tratar la enfermedad de Crohn de moderada a grave. Rinvoq está destinado a tratar a pacientes adultos que no pudieron ser tratados con éxito con fármacos candidatos que bloquean el factor de necrosis tumoral (TNF). En 2022, la FDA aprobó Skyrizi para el tratamiento de adultos con casos activos de enfermedad de Crohn de moderada a grave. •En 2021, AbbVie Inc. anunció el inicio del ensayo de fase 3 de risankizumab para el tratamiento de la enfermedad de Crohn. Risankizumab es un anticuerpo monoclonal humanizado que se dirige selectivamente a la vía de la interleucina-23 (IL-23). El ensayo tiene como objetivo evaluar la eficacia y seguridad de risankizumab en pacientes con enfermedad de Crohn de moderada a grave. En 2021, Takeda Pharmaceutical Company Limited anunció el inicio del ensayo de fase 3 del compuesto oral TAK-721 para el tratamiento de la enfermedad de Crohn. TAK-721 es un antagonista selectivo del receptor de quimiocinas CXCR3. El ensayo tiene como objetivo evaluar la eficacia y seguridad de TAK-721 en pacientes con enfermedad de Crohn de moderada a grave. Panorama competitivo y empresas clave:
Abbvie, Inc.; Johnson y Johnson Private Limited; GlaxoSmithKline Plc; Merck y Co., Inc.; Novartis Ag; Corporación Celgene; Genetech; Pfizer Inc.; Nestlé Ciencias de la Salud; y Boehringer Ingelheim GmbH se encuentran entre los actores destacados perfilados en el informe del mercado terapéutico de la enfermedad de Crohn. Además, durante el estudio se han estudiado y analizado varios otros actores para obtener una visión holística del mercado y su ecosistema. Estas empresas se centran en expansiones geográficas y lanzamientos de nuevos productos para satisfacer la creciente demanda de los consumidores de todo el mundo y ampliar su gama de productos con carteras especializadas. Su presencia global les permite atender a una gran base de clientes, lo que posteriormente facilita la expansión del mercado.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Crohn’s disease therapeutics market, based on drug class, is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain reliever. In 2023, the biologics segment held the largest Crohn’s disease therapeutics market share. The Crohn’s disease therapeutics market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy, online pharmacy. In 2023, the hospital pharmacy segment held the largest Crohn’s disease therapeutics market share and is anticipated to record the highest CAGR during 2023–2031.
The Crohn’s Disease Therapeutics Market majorly consists of the players such Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim Gmbh
Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.
Based on geography, the Crohn’s Disease Therapeutics Market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global Crohn’s Disease Therapeutics Market. Asia Pacific is expected to register the highest CAGR in the Crohn’s Disease Therapeutics Market during 2023–2031.
The increasing burden of irritable bowel syndrome, and the increasing in number of FDA approval and drug development bolster the Crohn’s disease therapeutics market size. However, the high cost of the treatment hinders the Crohn’s disease therapeutics market growth.
The List of Companies - Crohn's Disease Therapeutics Market
- ABBVIE, INC.
- JOHNSON AND JOHNSON PRIVATE LIMITED
- GLAXOSMITHKLINE PLC
- MERCK AND CO., INC.
- NOVARTIS AG
- CELGENE CORPORATION
- GENENTECH
- PFIZER INC.
- NESTLe HEALTH SCIENCE
- BOEHRINGER INGELHEIM GMBH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)